SKP2 and prostate cancer: For example, in both DRIVE and Achilles data sets, we noted that Rb-defective TCLs derived from prostate cancer, osteosarcoma, liver cancer and oesophageal cancer, exhibited sensitivity to SKP2 shRNA (Fig. 7g).